Immutep Ltd (IMMP)

$2.2

-0.06

(-2.65%)▲

Market is closed - opens 7 PM, 19 Apr 2024

Insights on Immutep Ltd

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 170.36K → 1.82M (in $), with an average increase of 48.7% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -19.27M → -21.22M (in $), with an average decrease of 10.1% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 46.7% return, outperforming this stock by 2.8%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 245.1% return, outperforming this stock by 276.4%

Performance

  • $2.16
    $2.33
    $2.20
    downward going graph

    1.82%

    Downside

    Day's Volatility :7.3%

    Upside

    5.58%

    downward going graph
  • $1.50
    $3.90
    $2.20
    downward going graph

    31.82%

    Downside

    52 Weeks Volatility :61.54%

    Upside

    43.59%

    downward going graph

Returns

PeriodImmutep LtdSector (Health Care)Index (Russel 2000)
3 Months
-0.44%
-0.7%
0.0%
6 Months
26.26%
6.6%
0.0%
1 Year
43.95%
3.7%
-1.5%
3 Years
-31.31%
14.0%
-21.8%

Highlights

Market Capitalization
275.9M
Book Value
$0.1
Earnings Per Share (EPS)
-0.25
Wall Street Target Price
7.58
Profit Margin
0.0%
Operating Margin TTM
-1095.72%
Return On Assets TTM
-25.7%
Return On Equity TTM
-42.12%
Revenue TTM
3.9M
Revenue Per Share TTM
0.04
Quarterly Revenue Growth YOY
25.2%
Gross Profit TTM
-32.8M
EBITDA
-41.3M
Diluted Eps TTM
-0.25
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    88%Buy
    11%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Immutep Ltd(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 244.55%

Current $2.20
Target $7.58

Company Financials

FY18Y/Y Change
Revenue
2.6M
↓ 37.69%
Net Income
-12.7M
↑ 36.07%
Net Profit Margin
-484.55%
↓ 262.66%
FY19Y/Y Change
Revenue
98.2K
↓ 94.69%
Net Income
-11.4M
↑ 27.65%
Net Profit Margin
-11.6K%
↓ 11155.46%
FY20Y/Y Change
Revenue
5.2M
↑ 5255.8%
Net Income
-9.3M
↓ 17.22%
Net Profit Margin
-179.9%
↑ 11460.11%
FY21Y/Y Change
Revenue
3.0M
↓ 47.0%
Net Income
-22.4M
↑ 122.02%
Net Profit Margin
-753.57%
↓ 573.67%
FY22Y/Y Change
Revenue
117.2K
↓ 95.71%
Net Income
-22.2M
↑ 7.72%
Net Profit Margin
-18.9K%
↓ 18152.94%
FY23Y/Y Change
Revenue
2.3M
↑ 1957.72%
Net Income
-26.6M
↑ 23.86%
Net Profit Margin
-1.1K%
↑ 17768.47%
Q3 FY22Q/Q Change
Revenue
111.0K
-
Net Income
-10.4M
-
Net Profit Margin
-9.4K%
-
Q4 FY22Q/Q Change
Revenue
1.1M
↑ 889.34%
Net Income
-14.1M
↑ 29.38%
Net Profit Margin
-1.2K%
↑ 8132.98%
Q3 FY23Q/Q Change
Revenue
1.8M
-
Net Income
-19.3M
-
Net Profit Margin
-1.1K%
-
FY18Y/Y Change
Total Assets
47.0M
↑ 34.42%
Total Liabilities
13.5M
↑ 59.84%
FY19Y/Y Change
Total Assets
28.5M
↓ 13.74%
Total Liabilities
11.3M
↑ 19.86%
FY20Y/Y Change
Total Assets
32.2M
↑ 14.94%
Total Liabilities
9.2M
↓ 17.68%
FY21Y/Y Change
Total Assets
61.5M
↑ 76.04%
Total Liabilities
6.6M
↓ 34.13%
FY22Y/Y Change
Total Assets
70.3M
↑ 24.55%
Total Liabilities
5.6M
↓ 7.61%
FY23Y/Y Change
Total Assets
98.3M
↑ 44.32%
Total Liabilities
7.3M
↑ 35.68%
Q3 FY22Q/Q Change
Total Assets
66.5M
↑ 0.0%
Total Liabilities
5.3M
↑ 0.0%
Q4 FY22Q/Q Change
Total Assets
58.6M
↓ 15.82%
Total Liabilities
6.4M
↑ 15.17%
Q2 FY23Q/Q Change
Total Assets
98.3M
-
Total Liabilities
7.3M
-
Q3 FY23Q/Q Change
Total Assets
147.4M
↑ 0.0%
Total Liabilities
11.0M
↑ 0.0%
Q4 FY23Q/Q Change
Total Assets
123.8M
↓ 16.05%
Total Liabilities
8.1M
↓ 25.81%
FY18Y/Y Change
Operating Cash Flow
-7.8M
↓ 8.58%
Investing Cash Flow
-11.9K
↑ 79.0%
Financing Cash Flow
18.4M
↓ 215812.22%
FY19Y/Y Change
Operating Cash Flow
-10.7M
↑ 96.57%
Investing Cash Flow
-29.1K
↑ 248.39%
Financing Cash Flow
5.6M
↓ 56.46%
FY20Y/Y Change
Operating Cash Flow
-7.5M
↓ 29.09%
Investing Cash Flow
-13.4K
↓ 53.3%
Financing Cash Flow
14.1M
↑ 155.57%
FY21Y/Y Change
Operating Cash Flow
-13.2M
↑ 62.74%
Investing Cash Flow
-11.7K
↓ 19.37%
Financing Cash Flow
39.5M
↑ 157.25%
FY22Y/Y Change
Operating Cash Flow
-20.8M
↑ 71.37%
Investing Cash Flow
-15.8K
↑ 46.88%
Financing Cash Flow
34.6M
↓ 4.47%
FY23Y/Y Change
Operating Cash Flow
-23.9M
↑ 18.7%
Investing Cash Flow
-55.2K
↑ 261.07%
Financing Cash Flow
50.7M
↑ 51.1%
Q3 FY22Q/Q Change
Operating Cash Flow
-19.7M
↑ 376.21%
Investing Cash Flow
-19.3K
↑ 220.45%
Financing Cash Flow
-44.3K
↑ 33.33%
Q4 FY22Q/Q Change
Operating Cash Flow
-3.8M
↓ 81.58%
Investing Cash Flow
-20.2K
↑ 0.0%
Financing Cash Flow
-43.1K
↓ 7.09%
Q1 FY23Q/Q Change
Operating Cash Flow
-9.5M
↑ 154.4%
Investing Cash Flow
-7.9K
↓ 60.26%
Financing Cash Flow
-30.9K
↓ 27.19%
Q2 FY23Q/Q Change
Operating Cash Flow
-5.6M
↓ 41.08%
Investing Cash Flow
-7.8K
↑ 0.0%
Financing Cash Flow
50.8M
↓ 165734.78%

Technicals Summary

Sell

Neutral

Buy

Immutep Ltd is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Immutep Ltd
Immutep Ltd
-6.61%
26.26%
43.95%
-31.31%
18.95%
Moderna, Inc.
Moderna, Inc.
-0.79%
20.27%
-27.48%
-36.11%
359.53%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-6.12%
9.1%
11.53%
80.35%
170.35%
Novo Nordisk A/s
Novo Nordisk A/s
-6.29%
23.82%
46.7%
242.59%
414.69%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.44%
6.95%
20.9%
79.35%
133.77%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Immutep Ltd
Immutep Ltd
NA
NA
NA
0.0
-0.42
-0.26
NA
0.1
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.71
25.71
1.46
45.13
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.58
46.58
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.42
28.42
0.53
16.73
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Immutep Ltd
Immutep Ltd
Buy
$275.9M
18.95%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$39.8B
359.53%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
170.35%
25.71
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$551.2B
414.69%
46.58
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.9B
133.77%
28.42
36.68%

Institutional Holdings

  • BlackRock Inc

    0.54%

  • Oracle Investment Management Inc

    0.43%

  • Meridian Wealth Management, LLC

    0.27%

  • Susquehanna International Group, LLP

    0.08%

  • Caption Management, LLC

    0.06%

  • Dimensional Fund Advisors, Inc.

    0.06%

Corporate Announcements

  • Immutep Ltd Earnings

    Immutep Ltd’s price-to-earnings ratio stands at None

    Read More

Company Information

immutep is a globally active biotechnology company, listed on the australian stock exchange and on the nasdaq global market in the us. as a leader in personalized bio-therapeutic products for cancer, immutep is dedicated to leveraging its current technology and expertise to develop innovative treatment options for patients and maximize value to shareholders. immutep's main pipeline of products is based on the lag-3 immune control mechanism which plays a vital role in the regulation of the t cell immune response. the most clinically advanced product is a t cell immunostimulatory factor (apc activator), imp321, for cancer chemoimmunotherapy which has completed early phase ii trials. a number of additional lag-3 products including antibodies for immune response modulation in autoimmunity and cancer are being developed by large pharmaceutical partners.

Organization
Immutep Ltd
Employees
0
CEO
Mr. Marc Voigt
Industry
Health Technology

Discover More

FAQs